Bill > HB314

Introduced Session

An Act To Be Known As The Ibogaine Drug Development Clinical Trial Act; To Authorize The Establishment Of A Consortium To Apply For Selection By The State Department Of Health To Conduct A Drug Development Clinical Trial With Ibogaine And Secure The United States Food And Drug Administration's (fda) Approval Of Ibogaine As A Medication For The Treatment Of Opioid Use Disorder, Co-occurring Substance Use Disorder, And Any Other Neurological Or Mental Health Condition For Which Ibogaine Demonstrates Efficacy; To Require The Consortium To Submit To The Department A Proposal For Purposes Of Conducting An Ibogaine Drug Development Clinical Trial, And Specify What The Proposal Must Include; To Provide That After Selecting A Consortium, The Department Shall Enter Into An Interagency Contract With The Consortium To Provide Funding To Implement The Consortium's Proposed Ibogaine Drug Development Clinical Trial; To Specify What The Interagency Contract Must Include; To Provide That The Department May Not Disburse Funds To Or For A Selected Consortium Under The Interagency Contract Until The Consortium Receives And The Department Verifies The Receipt Of Matching Funds From Sources Other Than The State; To Require The Selected Consortium To Enter Into An Agreement With The Lead Consortium Established By The Government Of Another State That Has Submitted An Investigational New Drug (ind) Application To The Fda And Has Requested A Breakthrough Therapy Designation For Ibogaine From The Fda; To Require The Selected Consortium To Work With The Fda To Coordinate The Drug Development Trial In Mississippi With Ibogaine Drug Development Trials That Are Being Conducted By The Lead Consortium And In Other States; To Provide That Only An Institution Of Higher Learning Or A Hospital May Serve As A Trial Site For Conducting An Ibogaine Drug Development Clinical Trial; To Provide For Allocation Of The Revenue Attributable To All Intellectual Property Rights And Other Commercial Rights Arising From The Drug Development Clinical Trial Conducted By A Consortium During The Period For Which The Trial Is Funded And Any Following Period Of Commercialization; To Provide That If Ibogaine Is Approved By The Fda To Treat A Medical Condition, A Physician Who Has Prescribed Ibogaine For A Patient Shall Supervise The Administration Of Ibogaine At A Hospital Or Other Licensed Health Care Facility To Ensure The Patient's Safety While The Patient Is Under The Influence Of Ibogaine; And For Related Purposes.

AI Summary

Committee Categories

Tracy Arnold (R)*,  Larry Byrd (R)*,  Lester Carpenter (R)*,  Samuel Creekmore IV (R)*, 

Approved by Governor (on 03/26/2026)

Bill Topics

Official Document